InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Safety Shot (NASDAQ: SHOT) Serves Court-Approved Notice of Action Against Capybara Research, Igor Appelboom, Responds to Ongoing Litigation Between GBB, FSD Pharma
January 17, 2024

InvestorNewsBreaks – Safety Shot (NASDAQ: SHOT) Serves Court-Approved Notice of Action Against Capybara Research, Igor Appelboom, Responds to Ongoing Litigation Between GBB, FSD Pharma

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, has filed a federal lawsuit in the United States District Court for the Southern District of New York. The litigation is against Capybara Research, a company that Safety Shot alleges was created solely to lend “credibility” to malicious and defamatory articles that it produced and distributed, articles that were “purposefully designed to negatively impact the share prices of publicly traded companies in which it holds short positions.” The suit also charged its previously anonymous owner and operator responsible for publishing a malicious and defamatory article authored and published on Nov. 22, 2023. According to the announcement, the article “attacked the company and its directors leading to a 37.03% decline in the company’s share price over the course of that day.” The announcement also noted that Safety Shot’s counsel at the Basile Law Firm, PC, discovered the true identity of the individual responsible for the publishing of the article, Igor Appelboom. After a series of court-approved unsuccessful attempts to serve Appelboom and Capybara Research, the company reported that “on Jan. 10, 2024, in a historic, first-of-its-kind order, the Honorable Jed S. Rakoff granted the company’s second motion permitting the company to serve notice of the action through this press release and associated Form 8-K filed on the Securities and Exchange Commission’s EDGAR database.” The announcement stated that by order of Rakoff, “this press release, the Form 8-K filed on Jan. 11, 2024, and the exhibits to the Form 8-K containing the company’s summons, complaint and the court’s Order, hereby provides the constitutional requirement of actual notice of the action to defendants Capybara Research and Igor Appelboom pursuant to Rule 4(f)(3) of the Federal Rules of Civil Procedure.”

In addition, Safety Shot announced that a federal court has refused to dismiss GBB Lab Inc.’s (“GBB”) ongoing lawsuit against FSD Pharma. The lawsuit is between FSD Pharma and GBB only. Safety Shot continues with the national launch of its highly anticipated wellness beverage, which is designed to help people feel better faster by reducing blood alcohol content and boosting clarity. “The Court’s decision to not dismiss GBB’s case demonstrates that we have a strong legal position based on the facts,” said GBB CEO John Gulyas. “We look forward to a full and fair proceeding to resolve this matter and we believe that we will be victorious.”

To view the full press releases, visit https://ibn.fm/HIDb3 and https://ibn.fm/mA5bn

About Safety Shot

Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Safety Shot will be available for retail purchase in the first week of December 2023. The company plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars in the first quarter of 2024. Safety Shot also plans to spin off legacy assets from its Jupiter Wellness business to unlock value for shareholders. For more information about the company, visit www.SafetyShotHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to SHOT are available in the company’s newsroom at https://ibn.fm/SHOT

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).